In BCR-ABL1-negative myeloproliferative neoplasms (MPNs) thrombo-hemorrhagic complications represent
the most common cause of morbidity and mortality. In particular, the reported overall
incidence of major thrombotic events ranges from 1.75 to 5.5% events patient-years
according to the specific MPN subtype [
[1]
]. Arterial thrombotic events, including ischemic stroke, acute coronary syndrome
and peripheral arterial thrombosis, account for the majority of these complications
(60–70%); accidents in the venous compartment, i.e. deep vein thrombosis, pulmonary
embolism, and superficial vein thrombosis, account instead for the remaining 30–40%
of the cases. Venous thrombosis can occur not only at common sites, but also at unusual
sites, including the cerebral or splanchnic circulation (SVT), the latter with a prevalence
ranging between 1 and 23%. A recent meta-analysis has confirmed that BCR-ABL1-negative MPNs can be identified in 30–50% of Budd-Chiari syndrome patients, and in
15–30% of those with portal vein thrombosis, representing the leading cause of SVT
[
[2]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Myeloproliferative neoplasms and thrombosis.Blood. 2013; 122: 2176-2184
- Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.Blood. 2012; 120: 4921-4928
- Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo clinic experience with 84 consecutive cases.Am. J. Hematol. 2018; 93: E61-E64
- The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.Mod. Pathol. 2017; 30: 169-179
- Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis.Ann. Hematol. 2015; 94: 881-882
- Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.Leuk. Res. 2015; 39: 525-529
- Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.Leuk. Res. 2014; 38: 155-160
- Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.Thromb. Haemost. 2016; 115: 240-249
- Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.Blood Cancer J. 2016; 6e493
Article info
Publication history
Published online: March 20, 2018
Accepted:
March 14,
2018
Received in revised form:
March 12,
2018
Received:
March 8,
2018
Identification
Copyright
© 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
